Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial
This study protocol will provide the research data of efficacy and safety of SJT for the treatment of acute uncomplicated lower UTI. The first aim is to determine whether Sanjin tablets can reduce the use of antibiotics; the second aim is to determine whether Sanjin tablets can substitute the use of antibiotics. The recurrence rate will be assessed after cured to determine whether SJT can reduce the recurrence rate. The results of this study will improve the rational use of drugs, especially the rational application of antibiotics. It will also enable safety evaluation from laboratory indices and adverse events, which will...
Source: Trials - July 19, 2019 Category: Research Source Type: clinical trials

Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Conditions:   Prophylaxis;   Stem Cell Transplant Complications Interventions:   Drug: Levofloxacin;   Drug: Ciprofloxacin Sponsor:   Henry Ford Health System Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2019 Category: Research Source Type: clinical trials

Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution
Condition:   Helicobacter Pylori Infection Interventions:   Drug: Levofloxacin film-coated tablet;   Drug: Levofloxacin intravenous solution Sponsor:   Mackay Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2019 Category: Research Source Type: clinical trials

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB
Condition:   Tuberculosis, Multidrug-Resistant Interventions:   Drug: Delamanid;   Drug: Levofloxacin;   Drug: Bedaquiline;   Drug: Clofazimine;   Drug: Linezolid;   Combination Product: WHO approved MDR-TB treatment regimens Sponsors:   Boston University;   United States Department of Defense;   Novartis Pharmaceuticals;   Pfizer;   Otsuka Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 4, 2019 Category: Research Source Type: clinical trials

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB. The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20 –24 months. The investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture conversion. The primary outcome is the treatment success rate at 24 months after tre...
Source: Trials - January 16, 2019 Category: Research Source Type: clinical trials

Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)
AbstractBackgroundMultidrug-resistant (MDR) tuberculosis (TB) presents a challenge for global TB control. Treating individuals with MDR-TB infection to prevent progression to disease could be an effective public health strategy. Young children are at high risk of developing TB disease following infection and are commonly infected by an adult in their household. Identifying young children with household exposure to MDR-TB and providing them with MDR-TB preventive therapy could reduce the risk of disease progression. To date, no trials of MDR-TB preventive therapy have been completed and World Health Organization guidelines ...
Source: Trials - December 20, 2018 Category: Research Source Type: clinical trials

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
Condition:   Acute Pyelonephritis Interventions:   Drug: Omadacycline;   Drug: Levofloxacin Sponsor:   Paratek Pharmaceuticals Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2018 Category: Research Source Type: clinical trials

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
Condition:   Acute Pyelonephritis Interventions:   Drug: Omadacycline;   Drug: Levofloxacin Sponsor:   Paratek Pharmaceuticals Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2018 Category: Research Source Type: clinical trials